Durvalumab

Durvalumab

Oncology

Indication extension

Bladder cancer

Extension of indication to include IMFINZI in combination with cisplatin-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with muscle invasive bladder cancer (MIBC)

Imfinzi

AstraZeneca

PD-1 / PD-L1 inhibitor

Intravenous

Intravenous drip

Intermural (MSZ)

PD-L1 remmer

Centralised (EMA)

Normal trajectory

No

2025

2026

Yes

Clinical trials

Chemotherapie en immuuntherapie

No estimate possible yet

1 times every 4 weeks

1500 mg

NCT03732677 (NIAGARA)

Neo-adjuvant 4 cycli, adjuvant q4w 8 cycli.

150 - 200

Market share is generally not included unless otherwise stated.

IKNL 2021; Fabrikant; experts werkgroepen

In 2021 waren er 459 diagnoses blaaskanker stadium 4. Fabrikant geeft aan dat het realistische patiëntvolume 412 patiënten bedraagt. De experts verwachten vergelijkbare patiëntvolumes zoals bij pembrolizumab met dezelfde indicatie, te weten 150 tot 200 patiënten.

83,808.00

fabrikant; G-standaard
https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2824%2903907-3

Dosering neo-adjuvant betreft 1.500mg IV Q3W (in combi met cis-gem) voor 4 cycles gevolgd door adjuvant 1.500mg IV Q4W voor 8 cycles  dus 4+8=12 cycles (1 flacon durvalumab is 500ml dus per cycle 3 flacons = €6.984 
12 cycles is dan €83.808 (op basis van apothekersinkoopprijs).

14,666,400.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

No

Yes

Buiten de indicaties in de Horizonscan Geneesmiddelen voor meerdere indicaties in ontwikkeling: Biliary cancer; Cervical cancer; Fallopian tube cancer; Head and neck cancer; Liver cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours.

adisinsight

Fase 3

There is currently no futher information available.